Eurofins Genoma Group

Come and discover all the advantages and functions of our web portal EurofinsNet! Simple, practical, fast. #webportal #EurofinsNet

Eurofins Genoma has been the first company to introduce NIPT (Non-Invasive Prenatal Testing) in Italy. For over 10 years, our mission has been focusing on continuous research and development to provide increasingly accurate and efficient screening. To achieve this, in addition to using cutting-edge technology, we employ advanced bioinformatic tools, built on the extensive experience in our laboratories. 🧬 The data derived from the analysis of over 70,000 women have allowed us to optimize the performance of our systems, enhancing the precision and reliability of our results. Each report undergoes a second validation by a team of specialists, including biologists and geneticists, to ensure the reliability and completeness of the information, addressing any limitations of the technology. Prenatalsafe has been supporting every expectant mother for over 10 years.

𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧 is the main tool in the fight against cancer. Awareness of breast cancer is crucial for early diagnosis. According to the National Cancer Institute (NCI), it is estimated that 5-10% of breast cancer cases may be associated with inherited genetic mutations. However, recent studies indicate that the overall hereditary component, including less well-known family factors, may reach 𝐮𝐩 𝐭𝐨 𝟏𝟓-𝟐𝟎%. The American Cancer Society emphasizes the importance of mutations in the BRCA1 and BRCA2 genes as significant risk factors for the development of breast cancer. In cases of 𝐟𝐚𝐦𝐢𝐥𝐲 𝐡𝐢𝐬𝐭𝐨𝐫𝐲 of breast cancer, it is essential to consider 𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 𝐚𝐧𝐝 𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐜𝐨𝐮𝐧𝐬𝐞𝐥𝐢𝐧𝐠, as these resources can provide valuable information for risk management and developing 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐩𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐦𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬. #BreastCancerAwareness #BreastCancer #OncologicalPrevention

Join us at the XXII National A.G.E.O. Congress 2024! It will be a unique opportunity to foster dialogue among participants while exploring the latest innovations in the health sector. The congress will cover significant topics such as Artificial Intelligence, Robotic Surgery, and Tissue Regeneration. We are pleased to share ideas and discover together the milestones we are achieving in our field. We look forward to welcoming many of you for a stimulating and enriching exchange! #EurofinsGenoma #AGEO2024 #Innovation #ArtificialIntelligence #RoboticSurgery #TissueRegeneration"

🌍✨ Today we celebrate World Food Day, an opportunity to reflect on the importance of healthy and conscious nutrition. In this context, it's crucial to recognize the role that genetics plays in our well-being, helping us understand how our bodies react to different nutrients. Genetics determines our metabolic predispositions, food intolerances, and the ability to absorb certain nutrients. Personalizing our diet based on genetic profiles can optimize health, enhance well-being, and prevent diseases. Eurofins Genoma aims to promote greater food awareness and help people live their best lives. Because every meal should be a step towards well-being! 🥗💚 #WorldFoodDay #Nutrition #FoodIntolerances #Wellness #Nutrinext #EubiomeGut

We are pleased to present the poster that was accepted and published at the National Congress of the SIM - Società Italiana di Microbiologia, held in Pavia from 8 to 11 September. 🔬The poster, produced in collaboration with UniCamillus International Medical University, presented a case study of approximately 200 patients tested by Eurofins Genoma for the vaginal microbiome. 🌟 Always excited to share our results with you and contribute to research! #Microbiology #Research #Microbiome

🧬 The role of the Gut Microbiome in Cancer Treatment Response 📊 Recent research continues to unveil the pivotal role that the gut microbiome plays in influencing human health, particularly by shaping systemic immune responses. Dysbiosis, or imbalance in gut flora, has been linked to various diseases such as inflammatory bowel disease, neurological disorders, and liver disease. But what’s even more groundbreaking is the emerging connection between the gut microbiome and cancer immunotherapy. New mechanistic studies and clinical trials have shown that the gut microbiota can directly modulate the response to immune checkpoint inhibitors (ICIs), potentially overcoming resistance to these therapies and improving patient outcomes. 📑 This recent review highlights the exciting progress being made in this area, offering fresh insights into how gut microbiome-based therapies may soon revolutionize cancer treatment by enhancing the efficacy of ICI immunotherapy. 💡 The microbiome is not just a bystander in our health—it could be a key player in future cancer therapies. 🔎 Read the article: https://lnkd.in/dvWEPqpP #Microbiome #CancerResearch #Immunotherapy #CancerTreatment #GutHealth #InnovationInMedicine #PrecisionMedicine #ClinicalResearch

Each person has a unique bacterial fingerprint, a distinctive profile of microorganisms that varies from individual to individual, while still containing common species. Three main variants, known as ENTEROTYPES, have been identified: 🔹 ENTEROTYPE B: characterised by a higher abundance of Firmicutes, typical of those with a diet rich in fats and proteins. 🔹 ENTEROTYPE P: characterised by a greater abundance of Prevotella, common in individuals with a carbohydrate-dominant diet. 🔹 ENTEROTYPE R: marked by a higher presence of Bacteroidetes, typical of those who have a varied diet with a high daily fibre intake. 💡 ENTEROTYPES are influenced by the microenvironment and lifestyle, meaning they can be modified. Some studies have shown that belonging to a particular enterotype can affect responses to therapies, such as oncological treatments. For this reason, identifying them is clinically significant. #genetictest #microbiota #gutmicrobiota #intestinalemicrobiota #enterotype

🏆 Nobel Prize in Physiology or Medicine 2024 🏆 Congratulations to Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNA (miRNA), a revolution that continues to unlock new frontiers in biomedical research. 🔎 The Eurofins Genoma research team has recently explored the potential of miRNA. We conducted a study analysing the mutational status of TP53 and the expression of circulating microRNA to assess the risk of locoregional recurrence. Serial biomarker monitoring allowed us to identify high-risk patients, paving the way for precise tracking of disease evolution and possible intensification of post-operative treatment. 👉 To learn more, read the article "Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer" https://lnkd.in/dHZZhqeY #NobelPrize #microRNA #biomedicalresearch #precisionmedicine #innovation